Liberum Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research note published on Wednesday morning, ThisIsMoney.Co.Uk reports.
A number of other equities analysts have also weighed in on AZN. Citigroup reiterated a buy rating and set a GBX 7,000 ($91.47) target price on shares of AstraZeneca in a research note on Monday, May 13th. Jefferies Financial Group lowered their target price on AstraZeneca from GBX 6,400 ($83.63) to GBX 6,350 ($82.97) and set a hold rating on the stock in a research note on Friday, May 24th. UBS Group reiterated a sell rating and set a GBX 5,400 ($70.56) target price on shares of AstraZeneca in a research note on Thursday, July 25th. Deutsche Bank reiterated a buy rating and set a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research note on Friday, July 26th. Finally, Goldman Sachs Group increased their target price on AstraZeneca from GBX 5,000 ($65.33) to GBX 5,500 ($71.87) and gave the stock a sell rating in a research note on Monday, August 5th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. AstraZeneca presently has an average rating of Hold and a consensus price target of GBX 6,688.24 ($87.39).
LON:AZN opened at GBX 7,256 ($94.81) on Wednesday. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The stock’s 50 day moving average price is GBX 6,772.74 and its two-hundred day moving average price is GBX 6,232.71. The firm has a market capitalization of $95.19 billion and a price-to-earnings ratio of 42.38. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 7,475.15 ($97.68).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: What is the strike price in options trading?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.